Statins in Chronic Kidney Disease: Cardiovascular Risk and Kidney Function

被引：16

作者：

Deedwania, Prakash C. ^{[1
]}

机构：

[1] Calif State Univ Fresno, San Francisco Sch Med, Fresno, CA 93740 USA

来源：

POSTGRADUATE MEDICINE | 2014年 / 126卷 / 01期

关键词：

cardiovascular risk; statins; renal function; chronic kidney disease; CORONARY-HEART-DISEASE; LOWERING LDL CHOLESTEROL; STAGE RENAL-DISEASE; C-REACTIVE PROTEIN; INTERVENTION TRIAL; URINARY PODOCYTES; THERAPY; ATORVASTATIN; OUTCOMES; PRAVASTATIN;

D O I：

10.3810/pgm.2014.01.2722

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Chronic kidney disease (CKD) represents a serious public health concern. It has been associated with a significant burden of cardiovascular disease and studies have linked decreases in estimated glomerular filtration rate to higher incidences of cardiovascular events and mortality. Evidence from randomized clinical trials have shown that statins are a safe and effective treatment for improving cardiovascular outcomes in primary and secondary cardiovascular disease prevention in patients with CKD; despite this, statins are often underutilized in these patients. In addition to cardiovascular benefits, statin therapy may be associated with improvements in renal function in patients with kidney disease. Some statin treatment regimens have been shown to slow decline in kidney function, and some trials have found that intensive statin therapy improved kidney function. This review examines improved cardiovascular outcomes with statin treatment in patients with CKD (excluding end-stage renal disease) and investigates the effects of statin therapy on kidney function.

引用

页码：29 / 36

页数：8

共 52 条

[1] End-stage renal disease, atherosclerosis, and cardiovascular mortality: Is C-reactive protein the missing link? [J].

Arici, M ;

Walls, J .

KIDNEY INTERNATIONAL, 2001, 59 (02) :407-414

[2]

AstraZeneca, PROSP EV PROT REN FU

[3]

AstraZeneca, 2013, DIAB PAT PROGR REN D

[4] The effect of statins versus untreated dyslipidaemia on renal function in patients with coronary heart disease. A subgroup analysis of the Greek atorvastatin and coronary heart disease evaluation (GREACE) study [J].

Athyros, VG ;

Mikhailidis, DP ;

Papageorgiou, AA ;

Symeonidis, AN ;

Pehlivanidis, AN ;

Bouloukos, VI ;

Elisaf, M .

JOURNAL OF CLINICAL PATHOLOGY, 2004, 57 (07) :728-734

[5] The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial [J].

Baigent, Colin ;

Landray, Martin J. ;

Reith, Christina ;

Emberson, Jonathan ;

Wheeler, David C. ;

Tomson, Charles ;

Wanner, Christoph ;

Krane, Vera ;

Cass, Alan ;

Craig, Jonathan ;

Neal, Bruce ;

Jiang, Lixin ;

Hooi, Lai Seong ;

Levin, Adeera ;

Agodoa, Lawrence ;

Gaziano, Mike ;

Kasiske, Bertram ;

Walker, Robert ;

Massy, Ziad A. ;

Feldt-Rasmussen, Bo ;

Krairittichai, Udom ;

Ophascharoensuk, Vuddidhej ;

Fellstrom, Bengt ;

Holdaas, Hallvard ;

Tesar, Vladimir ;

Wiecek, Andrzej ;

Grobbee, Diederick ;

de Zeeuw, Dick ;

Gronhagen-Riska, Carola ;

Dasgupta, Tanaji ;

Lewis, David ;

Herrington, William ;

Mafham, Marion ;

Majoni, William ;

Wallendszus, Karl ;

Grimm, Richard ;

Pedersen, Terje ;

Tobert, Jonathan ;

Armitage, Jane ;

Baxter, Alex ;

Bray, Christopher ;

Chen, Yiping ;

Chen, Zhengming ;

Hill, Michael ;

Knott, Carol ;

Parish, Sarah ;

Simpson, David ;

Sleight, Peter ;

Young, Alan ;

Collins, Rory .

LANCET, 2011, 377 (9784) :2181-2192

[6] Statins decrease all-cause mortality only in CKD patients not requiring dialysis therapy-A meta-analysis of 11 randomized controlled trials involving 21,295 participants [J].

Barylski, Marcin ;

Nikfar, Shekoufeh ;

Mikhailidis, Dimitri P. ;

Toth, Peter P. ;

Salari, Pooneh ;

Ray, Kausik K. ;

Pencina, Michael J. ;

Rizzo, Manfredi ;

Rysz, Jacek ;

Abdollahi, Mohammad ;

Nicholls, Stephen J. ;

Banach, Maciej .

PHARMACOLOGICAL RESEARCH, 2013, 72 :35-44

[7] A controlled, prospective study of the effects of atorvastatin on proteinuria and progression of kidney disease [J].

Bianchi, S ;

Bigazzi, R ;

Caiazza, A ;

Campese, VM .

AMERICAN JOURNAL OF KIDNEY DISEASES, 2003, 41 (03) :565-570

[8] Effects of Atorvastatin on Kidney Outcomes and Cardiovascular Disease in Patients With Diabetes: An Analysis From the Collaborative Atorvastatin Diabetes Study (CARDS) [J].

Colhoun, Helen M. ;

Betteridge, D. John ;

Durrington, Paul N. ;

Hitman, Graham A. ;

Neil, H. Andrew W. ;

Livingstone, Shona J. ;

Charlton-Menys, Valentine ;

DeMicco, David A. ;

Fuller, John H. .

AMERICAN JOURNAL OF KIDNEY DISEASES, 2009, 54 (05) :810-819

[9]

Collins AJ, 2012, AM J KIDNEY DIS S, V59, pevii

[10] US Renal Data System 2011 Annual Data Report [J].

Collins, Allan J. ;

Foley, Robert N. ;

Chavers, Blanche ;

Gilbertson, David ;

Herzog, Charles ;

Johansen, Kirsten ;

Kasiske, Bertram ;

Kutner, Nancy ;

Liu, Jiannong ;

St Peter, Wendy ;

Guo, Haifeng ;

Gustafson, Sally ;

Heubner, Brooke ;

Lamb, Kenneth ;

Li, Shuling ;

Li, Suying ;

Peng, Yi ;

Qiu, Yang ;

Roberts, Tricia ;

Skeans, Melissa ;

Snyder, Jon ;

Solid, Craig ;

Thompson, Bryn ;

Wang, Changchun ;

Weinhandl, Eric ;

Zaun, David ;

Arko, Cheryl ;

Chen, Shu-Cheng ;

Daniels, Frank ;

Ebben, James ;

Frazier, Eric ;

Hanzlik, Christopher ;

Johnson, Roger ;

Sheets, Daniel ;

Wang, Xinyue ;

Forrest, Beth ;

Constantini, Edward ;

Everson, Susan ;

Eggers, Paul ;

Agodoa, Lawrence .

AMERICAN JOURNAL OF KIDNEY DISEASES, 2012, 59 (01) :EVII-E418

← 1 2 3 4 5 6 →